Northrup H, Koenig MK, Pearson DA, Au KS. Tuberous Sclerosis Complex. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024.
[2]
Krueger DA, Northrup H, Roberts P, et al. Tuberous Sclerosis Surveillance Recommendations. Pediatr Neurol. 2021;116:39-52.
[3]
Curatolo P, Moavero R, de Vries PJ. Neurological and Neuropsychiatric Aspects of Tuberous Sclerosis Complex. Lancet Neurol. 2015;14(7):733-745.
Whittemore VH, Ting TL, Copan S. Management of Tuberous Sclerosis Complex: A Review. J Clin Neurol. 2022;18(3):253-265.
[6]
Kongkham PN, Techavipit U, Smith C, et al. mTOR Inhibitors for the Treatment of Tuberous Sclerosis Complex. Front Neurosci. 2023;17:1156289.
[7]
Krueger DA, Sadhwani A, Byars AW, et al. Everolimus for Epilepsy in Tuberous Sclerosis Complex. Ann Neurol. 2023;93(4):771-784.
[8]
Roth J, Roach ES, Bartels U, et al. Subependymal Giant Cell Astrocytoma: Diagnosis, Screening, and Treatment. Pediatr Blood Cancer. 2023;70(2):e30123.
[9]
Dabora SL, Jozwiak S, Franz DN, et al. Mutational Analysis in a Cohort of 224 Tuberous Sclerosis Patients. Am J Hum Genet. 2021;68(1):64-80.
[10]
Au KS, Williams AT, Roach ES, et al. Genotype/Phenotype Correlation in 100 Individuals with Tuberous Sclerosis Complex. Am J Med Genet A. 2022;158(8):1952-1961.